Oncolytic Vaccinia virus safely and effectively treats skin tumors in mouse models of xeroderma pigmentosum

International Journal of Cancer

Volumn 132, Issue 3, 2013, Pages 726-731

  Brun, Jan ^a,b   Mahoney, Douglas J ^a,b,e   Le Boeuf, Fabrice ^c   Lefebvre, Charles ^a   Sanaei, Cina A ^a   Falls, Theresa ^c   McCart, J Andrea ^d   Stojdl, David F ^a,b  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

^e ALBERTA CHILDREN S HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

cancer; oncolytic; virus; xeroderma pigmentosum

Indexed keywords

ONCOLYTIC VACCINIA VIRUS; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; DNA REPAIR; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GENETIC MODEL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; SINGLE DRUG DOSE; TUMOR XENOGRAFT; VIRUS STRAIN; XERODERMA PIGMENTOSUM;

ANIMALS; CELL LINE, TUMOR; MELANOMA; MICE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; SKIN NEOPLASMS; VACCINIA VIRUS; XERODERMA PIGMENTOSUM;

EID: 84870252791     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27695     Document Type: Article

References (25)

1. Cordonnier AM, Fuchs RP,. Replication of damaged DNA: molecular defect in xeroderma pigmentosum variant cells. Mutat Res 1999; 435: 111-9.
2. Hoeijmakers JH,. Genome maintenance mechanisms for preventing cancer. Nature 2001; 411: 366-74.
3. Kraemer KH, Lee MM, Scotto J,. Xeroderma pigmentosum. Cutaneous, ocular, and neurologic abnormalities in 830 published cases. Arch Dermatol 1987; 123: 241-50.
4. Rechkunova NI, Krasikova YS, Lavrik OI,. Nucleotide excision repair: DNA damage recognition and preincision complex assembly. Biochemistry (Mosc) 2011; 76: 24-35.
5. Magnaldo T,. Xeroderma pigmentosum: from genetics to hopes and realities of cutaneous gene therapy. Expert Opin Biol Ther 2004; 4: 169-79.
6. Sinkovics JG, Horvath JC,. Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers. Arch Immunol Ther Exp (Warsz) 2008; 56 (Suppl 1): 3s-59s.
7. Vaha-Koskela MJ, Heikkila JE, Hinkkanen AE,. Oncolytic viruses in cancer therapy. Cancer Lett 2007; 254: 178-216.
8. Brun J, McManus D, Lefebvre C, et al. Identification of genetically modified Maraba virus as an oncolytic rhabdovirus. Mol Ther 2010; 18: 1440-9.
9. Mastrangelo MJ, Maguire HC, Jr., Eisenlohr LC, et al. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 1999; 6: 409-22.
10. Traktman P,. Poxviruses: an emerging portrait of biological strategy. Cell 1990; 62: 621-6.
11. Kim JH, Oh JY, Park BH, et al. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther 2006; 14: 361-70.
12. McCart JA, Ward JM, Lee J, et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 2001; 61: 8751-7.
13. de Vries A, van Oostrom CT, Hofhuis FM, et al. Increased susceptibility to ultraviolet-B and carcinogens of mice lacking the DNA excision repair gene XPA. Nature 1995; 377: 169-73.
14. Sands AT, Abuin A, Sanchez A, et al. High susceptibility to ultraviolet-induced carcinogenesis in mice lacking XPC. Nature 1995; 377: 162-5.
15. Nakane H, Takeuchi S, Yuba S, et al. High incidence of ultraviolet-B-or chemical-carcinogen-induced skin tumors in mice lacking the Xeroderma pigmentosum group A gene. Nature 1995; 377: 165-8.
16. DiGiovanni J,. Multistage carcinogenesis in mouse skin. Pharmacol Ther 1992; 54: 63-128.
17. Parato KA, Breitbach CJ, Le Boeuf F, et al. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther 2011; 20: 749-58.
18. Thorne SH, Hwang TH, O'Gorman WE, et al. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J Clin Invest 2007; 117: 3350-8.
19. Keijzer W, Mulder MP, Langeveld JC, et al. Establishment and characterization of a melanoma cell line from a xeroderma pigmentosum patient: activation of N-ras at a potential pyrimidine dimer site. Cancer Res 1989; 49: 1229-35.
20. Breitbach CJ, Paterson JM, Lemay CG, et al. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther J Am Soc Gene Ther 2007; 15: 1686-93.
21. Kirn DH, Thorne SH,. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 2009; 9: 64-71.
22. Buller RM, Palumbo GJ,. Poxvirus pathogenesis. Microbiol Rev 1991; 55: 80-122.
23. Park BH, Hwang T, Liu TC, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 2008; 9: 533-42.
24. Hwang TH, Moon A, Burke J, et al. A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol Ther 2011; 19: 1913-22.
25. Wijnhoven SW, Sonneveld E, Kool HJ, et al. Chemical carcinogens induce varying patterns of LOH in mouse T-lymphocytes. Carcinogenesis 2003; 24: 139-44.